Browse
Explore conditions, clinical trials, and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
116076 trials found · Page 1617 of 5804
-
Zapping just a few spots: new hope for patients with worsening metastatic cancer?
Disease control OngoingSystemic therapy is the main treatment for patients with metastatic cancers. Oligo-progression has become a recognized entity for metastatic cancer and it is thought that a subset of cancer cells may develop heterogeneity and resistant clones while receiving systemic therapy. Thi…
Phase: NA • Sponsor: University Health Network, Toronto • Aim: Disease control
Last updated Jun 27, 2026 13:02 UTC
-
New pill aimed at Hard-to-Treat lung cancer shows early promise
Disease control OngoingThis is a prospective one-arm, two-stage phase 2 trial of TVB-2640 in KRAS mutant NSCLC patients. 13 patients will be treated with a minimum of 1 cycle of TVB-2640 therapy over 8 weeks.
Phase: PHASE2 • Sponsor: David E Gerber • Aim: Disease control
Last updated Jun 27, 2026 12:37 UTC
-
Stem cell combo shows promise for Parkinson's in small trial
Disease control CompletedAn experimental study will be conducted at Iffat Anwar medical complex conducted to evaluate the effectiveness of PRP and stem Cell therapy in the treatment of PD. After the initial cognitive and laboratory testing, the first infusion appointment will be planned within 2 weeks. …
Phase: NA • Sponsor: Fatima Jinnah Medical University • Aim: Disease control
Last updated Jun 27, 2026 08:08 UTC
-
New Lung-Clearing device could ease breathing for kids with cystic fibrosis
Symptom relief CompletedChest physiotherapy plays a crucial role in treatment of lung disease in cystic fibrosis (CF). New airway clearance techniques (ACTs) adapted to individual needs are still being sought to achieve the best effect of airway clearance. The primary aim of this study is to assess the …
Phase: NA • Sponsor: Physio-Assist • Aim: Symptom relief
Last updated Jun 27, 2026 07:51 UTC
-
New machine may help 'Marginal' donor livers work better after transplant
Disease control CompletedGiven the scarce donor supply, an increasing number of so-called marginal or extended criteria donor (ECD) organs have been used for liver transplantation. These ECD liver grafts are, however, known to be associated with a higher rate of early allograft dysfunction (EAD) and prim…
Phase: NA • Sponsor: Hospices Civils de Lyon • Aim: Disease control
Last updated Jun 27, 2026 07:58 UTC
-
New combo attack on returning prostate cancer shows promise
Disease control CompletedThis phase II trial studies how well surgery and radiation therapy work in treating patients with prostate cancer that has come back or spread to other parts of the body. Radiation therapy uses high energy beams to kill tumor cells and shrink tumors. Surgical procedures, such as …
Phase: PHASE2 • Sponsor: University of Utah • Aim: Disease control
Last updated Jul 24, 2026 00:00 UTC
-
New hope for liver cancer patients: cabozantinib safety trial shows promise
Disease control CompletedHepatocellular carcinoma (HCC) is a common tumor (the 8th leading cause of cancer in France) and has a poor prognosis. It is the 3rd leading cause of cancer deaths in the world. In the early stages (low tumor mass), HCC can be treated for curative purposes by surgical resection, …
Phase: PHASE4 • Sponsor: Hospices Civils de Lyon • Aim: Disease control
Last updated Jun 27, 2026 08:00 UTC
-
Spinal implant aims to stabilize the back and ease pain
Disease control CompletedA 2 and 5 year evaluation of clinical outcomes in the treatment of degenerative spinal stenosis with concomitant low back pain by decompression with additional stabilization using the coflex® Interlaminar Technology for FDA Actual Conditions of Use Study.
Phase: NA • Sponsor: Companion Spine, LLC • Aim: Disease control
Last updated Jul 04, 2026 00:00 UTC
-
Blood cancer drug venetoclax gets Long-Term safety check
Disease control OngoingThe purpose of this extension study is to provide venetoclax and obtain long-term safety data for subjects who continue to tolerate and derive benefit from receiving venetoclax in ongoing studies.
Phase: PHASE3 • Sponsor: AbbVie • Aim: Disease control
Last updated Jun 27, 2026 12:33 UTC
-
New combo therapy shows promise for Hard-to-Treat cancers
Disease control OngoingThe primary purpose of the study is to evaluate safety and tolerability of E7389 liposomal formulation (E7389-LF) in combination with nivolumab and to determine the recommended Phase 2 dose (RP2D) in Phase 1b part and to evaluate objective response rate (ORR) of E7389-LF and nivo…
Phase: PHASE1, PHASE2 • Sponsor: Eisai Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 09:03 UTC
-
New hope for ulcerative colitis: extended trial tests Long-Term relief
Disease control OngoingThe purpose of this open-label extension (OLE) study is to evaluate the safety and efficacy of etrasimod in participants with moderately to severely active ulcerative colitis (UC) who previously received double-blind treatment (either etrasimod 2 mg per day or placebo) during par…
Phase: PHASE3 • Sponsor: Pfizer • Aim: Disease control
Last updated Jul 11, 2026 00:00 UTC
-
Could a lower warfarin dose cut bleeding risk in valve patients?
Disease control Recruiting nowThis study evaluates the use of a lower INR target (1.5 to 2.5) in patients with a mechanical bileaflet heart valve in the aortic position. This study will inform physicians about whether a lower INR target will decrease the risk of bleeding or increase the risk of blood clot for…
Phase: PHASE3 • Sponsor: Population Health Research Institute • Aim: Disease control
Last updated Jun 27, 2026 08:09 UTC
-
New drug targets Hard-to-Treat cancers with MET mutations
Disease control OngoingA phase 1/2, first-in-human, open-label study of the safety, tolerability, PK, and efficacy of the novel MET/CSF1R/SRC inhibitor TPX-0022 in adult subjects with advanced or metastatic NSCLC, Gastric Cancer, or solid tumors harboring genetic alterations in MET. (SHIELD-I)
Phase: PHASE1 • Sponsor: Turning Point Therapeutics, Inc. • Aim: Disease control
Last updated Jun 27, 2026 07:52 UTC
-
Surgery or strength? new study pits hip replacement against exercise for arthritis pain
Disease control OngoingHip osteoarthritis is associated with joint pain, physical disability, decreased muscle strength and poor health status, and the most common cause for total hip arthroplasty. No studies have investigated the effect of total hip arthroplasty compared to non-surgical treatment in p…
Phase: NA • Sponsor: Vejle Hospital • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
Smart insulin systems may shield hearts in type 1 diabetes
Disease control OngoingThis is a prospective, non-randomized, observational cohort study conducted in adult patients with type 1 diabetes.Participants with poorly controlled T1D under multiple daily injection (MDI) treatment will be assigned to one of three treatment groups: 1. hybrid closed-loop syst…
Sponsor: Attikon Hospital • Aim: Disease control
Last updated Jun 27, 2026 07:59 UTC
-
Could a sleep machine boost stroke recovery?
Disease control Recruiting nowThe proposed study is a randomized controlled trial among an anicipated 180 participants with acute ischemic stroke and mod/severe OSA diagnosed by ambulatory polysomnography (PSG) comparing PAP treatment with usual care concerning the primary outcome of functional recovery.
Phase: NA • Sponsor: Yale University • Aim: Disease control
Last updated Jun 26, 2026 13:36 UTC
-
Promising combo for lymphoma hits early snag – trial stopped
Disease control TerminatedThis research is being done to assess Umbralisib and Rituximab as a first line therapy for Follicular Lymphoma or Marginal Zone Lymphoma.
Phase: PHASE2 • Sponsor: Massachusetts General Hospital • Aim: Disease control
Last updated Jun 27, 2026 09:09 UTC
-
Scientists dive deep into kidney tissue to unlock secrets of disease
Knowledge-focused Recruiting nowAcute kidney injury (AKI) and chronic kidney disease (CKD) impose a significant global health burden. Yet, no effective therapies currently exist for AKI, and only a few are available for CKD. Despite significant effort from industry and academia, development of pharmacologic th…
Sponsor: Icahn School of Medicine at Mount Sinai • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:08 UTC
-
Could a simple hormone shot improve IVF live birth rates?
Disease control Recruiting nowThe objectives of this study are to compare the efficacy of the dual trigger group vs the hCG trigger group on the live birth rate in women undergoing IVF and the efficacy of the agonist in LP group vs the placebo group on the live birth rate in women undergoing FET.
Phase: PHASE3 • Sponsor: The University of Hong Kong • Aim: Disease control
Last updated Jun 27, 2026 12:33 UTC
-
Can a cancer drug slow down a rare leukemia?
Disease control OngoingThis study is to find out if treating Chronic Myelomonocytic Leukemia (CMML) with a study drug (ruxolitinib) can improve outcomes of patients with CMML.
Phase: PHASE2 • Sponsor: H. Lee Moffitt Cancer Center and Research Institute • Aim: Disease control
Last updated Jul 03, 2026 00:00 UTC